Detecting amyloid and tau pathology in Parkinson’s disease, 4R-tauopathies and control subjects with plasma pTau217
Plasma pTau217 levels serve as a scalable, non-invasive marker of AD-pathology across Lewy body diseases, PSP/CBS, and MCI/CU populations. AD co-pathology independently contributes to cognitive deficits in PD, but not in PSP/CBS.
Authors
- Giulia Bonato
- Eleonora Fiorenzato (ORCID: https://orcid.org/0000-0001-7947-5903)
- Carmelo Fogliano
- Martina Montagnana (ORCID: https://orcid.org/0000-0001-8999-0001)
- Diego Cecchin (ORCID: https://orcid.org/0000-0001-7956-1924)
- Marta Campagnolo (ORCID: https://orcid.org/0000-0002-6394-7168)
- Angelo Antonini (ORCID: https://orcid.org/0000-0003-1040-2807)
- Giulia Musso (ORCID: https://orcid.org/0000-0002-7748-773X)
- Chiara Cosma (ORCID: https://orcid.org/0000-0002-0678-0277)
- Fábio Vianello (ORCID: https://orcid.org/0000-0002-4874-7205)
- Miryam Carecchio (ORCID: https://orcid.org/0000-0002-0755-5477)
- Andrea Guerra (ORCID: https://orcid.org/0000-0001-6601-4964)
- Simone Cauzzo (ORCID: https://orcid.org/0000-0002-9237-5269)
- Roberta Biundo (ORCID: https://orcid.org/0000-0001-5846-755X)
- Wassilios G. Meissner (ORCID: https://orcid.org/0000-0003-2172-7527)
- Annachiara Cagnin
- Valentina Misenti
Institutions
- Centre National de la Recherche Scientifique (FR)
- University of Padua (IT)
- Université de Bordeaux (FR)
- Institut des Maladies Neurodégénératives (FR)
- IRCCS San Camillo Hospital (IT)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-08-15
- DOI
- https://doi.org/10.3389/fneur.2025.1638852
- Citations
- 2
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- European Commission
- Università degli Studi di Padova